QDEL at a glance
QuidelOrtho Corp (QDEL, SEC CIK 1906324) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on September 23, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 28, 2025 (FY2025), QuidelOrtho Corp (QDEL) reported revenue of $2.7 billion (down 1.9% from FY2024) and a net loss of $1.1 billion. Diluted EPS was -$16.69.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding QuidelOrtho Corp (QDEL) shares worth $709.9 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.7B
- −1.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 28 funds
- $709.9M · +0 vs prior quarter
- Latest 8-K
- Sep 23, 2026
- Item 1.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 28, 2025
Business Overview
- Core business model: global diagnostics provider specializing in immunoassay, molecular testing, clinical chemistry, transfusion medicine, and POC solutions
- Initiated wind-down of U.S. donor screening portfolio (VIP platform, microplate assays) starting Feb 2024, expected substantially complete by mid-2026
- New emphasis on advancing digital solutions with launch of QuidelOrtho RESULTS MANAGER and planned 2026 releases of automation and informatics products
- R&D spend $186.2M in 2025, down from $218.7M in 2024, reflecting project phase transitions and continued innovation investment
- Customer service innovation highlighted by being first medical device company awarded global ISO Excellence Services Label in EMEA region
Risk Factors
- Legal/regulatory risk: FDA EUA approvals and compliance with anti-bribery and data privacy laws impacting product commercialization and operations
- Geopolitical/macro risk: April 2025 U.S. tariffs on imports from U.K., Canada, Mexico, China causing incremental supply chain and shipping costs
- Operational/supply chain risk: Concentration in California facilities near earthquake/fire faults posing disruption risk to manufacturing and product delivery
- Competitive risk: Distributors developing own competitive products and exclusive agreements with rivals threatening key sales channels
- Financial risk: Customer concentration with significant revenues from few distributors; loss would materially disrupt sales and financial results
Management Discussion & Analysis
- Revenue $2,730.2M FY25, down 2% YoY from $2,782.9M; FY24 down 7% YoY from $2,997.8M, COVID-19 product declines primary driver
- Operating margin approx. 20.1% FY25 (Operating expenses $1,488.9M = 54.5% of revenue), cost of sales 53.3% vs 53.8% in FY24; margin benefit from cost savings initiatives
- Best segment growth: EMEA revenue up 7% to $360.7M, Adjusted EBITDA up 78% to $82.6M; worst segment: Donor Screening revenue down 54% to $52.6M due to U.S. wind-down
- Operating cash flow pressures from restructuring charges: Restructuring charges $263.6M in FY25 vs $127.2M in FY24; buybacks/dividends details not provided; capital spending not detailed
- Outlook cautious: Ongoing COVID/endemic dynamics, competitive pressures, pricing pressures, geopolitical tariffs risks; restructuring and strategic refocus ongoing to improve financials
AI summary of the QDEL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 28, 2026
Management Discussion & Analysis
- Revenue $630.9M, up 3% YoY from $613.9M
- Cost of sales margin 56.7% vs 55.2% YoY
- Best product line Point of Care $108.2M, up 16% YoY
- Worst product line Molecular Diagnostics $1.6M, down 71% YoY
- Outlook: weaker respiratory season may continue pressuring flu and COVID-19 testing through second half 2026
Risk Factors
- No material changes to previously disclosed risk factors from the 2025 Annual Report
- Regulatory compliance risk: no new developments identified in the quarterly filing
- Operational risk: existing Annual Report risks remain relevant without quarterly updates
- Financial risk: existing liquidity and debt risks remain unchanged from the Annual Report
AI summary of the QDEL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- Covenant relief through September 30, 2029, signaling elevated leverage or reduced earnings pressure
- Leverage cap eases to 5.50x through July 2, 2028, then tightens to 4.25x from September 30, 2029
Item 2.02: Results of Operations and Financial Condition
- Q2 FY2026 results covered quarter ended June 28, 2026
- Press release furnished as Exhibit 99.1, containing the financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q2 revenue $630.9M, up 2.8% reported and 1.9% constant currency, with 6.1% growth excluding China
- Point of Care revenue $108.2M, up 16.3%, while Labs excluding China grew 9.0%
Item 7.01: Regulation FD Disclosure
- Young appointed Chief Financial Officer, creating a new senior finance leadership transition
- Appointment disclosed under Regulation FD and furnished as Exhibit 99.1
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Micah Young becomes CFO and principal financial officer July 6, 2026, succeeding retiring Joseph Busky
- Young brings CFO experience from Masimo and finance leadership across medical-device companies
Item EX-99.1: Item EX-99.1
- CFO transition effective July 6, 2026, with Micah Young succeeding retiring CFO Joseph M. Busky
- Busky remaining as advisor, reducing near-term disruption and supporting continuity
AI summaries of QDEL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for QDEL
Don't miss the next QDEL filing
- Alerts as it files. A push when QDEL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut QDEL, by share count.
- Ask anything. An AI agent that reads every QDEL filing and answers with sources.
QDEL alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bowman Ronald Lee | F | Sep 15, 2026 | 921 | $10.63 |
| Bowman Ronald Lee | M | Sep 15, 2026 | 2,566 | - |
| Bowman Ronald Lee | M | Sep 15, 2026 | 2,566 | - |
| Hanson Bryan Michael | M | Aug 15, 2026 | 446 | - |
| Hanson Bryan Michael | M | Aug 15, 2026 | 446 | - |
| Hanson Bryan Michael | F | Aug 15, 2026 | 162 | $14.30 |
| Young Micah W | A | Jul 15, 2026 | 356,555 | - |
| Hanson Bryan Michael | F | Jul 1, 2026 | 2,096 | $18.18 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.8B | $2.7B |
| Operating Income | - | -$2.0B | -$919.2M |
| Net Income | -$10.1M | -$2.1B | -$1.1B |
| Op. Margin | - | -70.5% | -33.7% |
| Net Margin | - | -73.7% | -41.5% |
| Balance Sheet | |||
| Total Assets | $8.6B | $6.4B | $5.8B |
| Equity | - | $3.0B | $1.9B |
| ROE | - | -68.8% | -58.9% |
| Per Share | |||
| EPS | $-0.15 | $-30.54 | $-16.69 |
| Cash Flow | |||
| Operating CF | - | $83.0M | $105.2M |
| CapEx | $209.3M | $195.1M | $188.2M |
Source: XBRL data in QuidelOrtho Corp (QDEL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate QDEL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $709.9M |
| Q1 2026 | 28 | $650.5M |
| Q4 2025 | 27 | $1.10B |
| Q3 2025 | 27 | $1.08B |
| Q2 2025 | 26 | $1.05B |
| Q1 2025 | 24 | $903.4M |
| Q4 2024 | 22 | $938.5M |
| Q3 2024 | 19 | $815.9M |
- FMR LLC (Fidelity)+772.5K (+12%)
- BlackRock+753.4K (+7%)
- AQR Capital Management+736.4K (+421%)
- Morgan Stanley+652.0K (+64%)
- Millennium Management+440.3K (+156%)
- Dimensional Fund Advisors−1.80M (-59%)
- Goldman Sachs Group−1.35M (-56%)
- Raymond James Financial−63.0K (-82%)
- Fifth Third Bancorp−29.0K (-53%)
- Bank of America Corp−25.1K (-20%)
- Two Sigma Investments+17.4K
- Allstate−32.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 201 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
QDEL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| SC 13G | Aug 13, 2026 | - | - | |
| 10-Q | Aug 7, 2026 | Jun 28, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 16, 2026 | - | - | - |
| SC 13G | Jul 8, 2026 | - | - | |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - |
Related Health Care companies
- TKNO · Alpha Teknova, Inc.In Vitro & In Vivo Diagnostic Substances
- CLDX · Celldex Therapeutics, Inc.In Vitro & In Vivo Diagnostic Substances
- IDXX · Idexx LaboratoriesIn Vitro & In Vivo Diagnostic Substances
- NTLA · Intellia Therapeutics, Inc.In Vitro & In Vivo Diagnostic Substances
- LNTH · Lantheus Holdings, Inc.In Vitro & In Vivo Diagnostic Substances
- MYGN · MYRIAD GENETICS INCIn Vitro & In Vivo Diagnostic Substances
- NEOG · NEOGEN CORPIn Vitro & In Vivo Diagnostic Substances
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
QDEL SEC filings: frequently asked questions
Which institutions hold QDEL stock?
As of June 30, 2026, the largest QuidelOrtho Corp (QDEL) holders among the 13F filers tracked by SignalX were BlackRock ($196.2 million), FMR LLC (Fidelity) ($129.0 million), Vanguard Portfolio Management LLC ($72.4 million), Invesco Ltd ($60.8 million), Vanguard Capital Management LLC ($53.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was QDEL's revenue in fiscal year 2025?
For the fiscal year ended December 28, 2025 (FY2025), QuidelOrtho Corp (QDEL) reported revenue of $2.7 billion (down 1.9% from FY2024) and a net loss of $1.1 billion. Diluted EPS was -$16.69. The figures come from the XBRL data in the 10-K.
What are the main risks in QDEL's latest 10-K?
In the 10-K filed February 19, 2026, QuidelOrtho Corp (QDEL) flagged: Legal/regulatory risk: FDA EUA approvals and compliance with anti-bribery and data privacy laws impacting product commercialization and operations. Geopolitical/macro risk: April 2025 U.S. tariffs on imports from U.K., Canada, Mexico, China causing incremental supply chain and shipping costs. (AI summary of the Risk Factors section.)
What did QDEL report in its latest 8-K?
QuidelOrtho Corp (QDEL) filed an 8-K on September 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Covenant relief through September 30, 2029, signaling elevated leverage or reduced earnings pressure.
What are the latest QDEL SEC filings?
QuidelOrtho Corp (QDEL) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on September 23, 2026 and a Form 4 insider filing on September 17, 2026.
What is QDEL's SEC CIK number?
QuidelOrtho Corp (QDEL)'s SEC Central Index Key (CIK) is 1906324. EDGAR lists every QDEL filing under that number.
Ask anything about QDEL
The research agent reads QDEL's filings, financials, insider trades and 13F holders, then answers with sources.